Skip to Main Content

In a decision with implications for health care costs, a federal appeals court ruled drug makers cannot use state laws to punish their biosimilar rivals from withholding information about their medicines.

The ruling came in response to opposing views of a procedure found in the Biologics Price Competition and Innovation Act, which is supposed to determine when biosimilar drugs can be launched. A biosimilar drug is a nearly identical variant of a biologic and is expected to provide the same result in patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED